Zerograin-Plus Tablet is a combination pharmaceutical formulation containing Domperidone 10 mg, Flunarizine 5 mg, and Paracetamol 325 mg, designed for the management of nausea, migraine, and associated pain symptoms. Domperidone acts as a peripheral dopamine D2 receptor antagonist, facilitating gastric motility and providing effective relief from nausea and vomiting. Flunarizine, a calcium channel blocker with antihistaminic properties, is utilized for migraine prophylaxis by reducing neuronal excitability and preventing vasospasm. Paracetamol, a widely used analgesic and antipyretic agent, offers symptomatic relief from mild to moderate pain and fever. The synergistic combination in Zerograin-Plus Tablet targets multiple pathways involved in migraine pathophysiology and associated gastrointestinal disturbances, thereby enhancing therapeutic efficacy. This formulation is indicated for patients experiencing migraine attacks accompanied by nausea and headache, improving overall patient comfort and quality of life. Zerograin-Plus should be administered as per the prescribing physician’s instructions, considering contraindications such as hypersensitivity to any component, severe hepatic impairment, or existing cardiac conditions. Caution is advised in patients with a history of extrapyramidal symptoms or Parkinson’s disease. Common adverse effects may include dry mouth, dizziness, or gastrointestinal discomfort. Regular monitoring and adherence to recommended dosages are essential to ensure safety and optimal therapeutic outcomes.